Macrophages have a key role in tumor-associated pulmonary inflammation that supports the proliferation of tumor cells and promotes lung tumor growth. Although increased numbers of tumor-associated macrophages are linked to poor prognosis in lung cancer patients, little is known regarding the transcriptional mechanisms controlling recruitment of macrophages during lung tumorigenesis. Forkhead Box m1 (Foxm1) transcription factor is induced in multiple cell types within tumor lesions and its increased expression is associated with poor prognosis in patients with lung adenocarcinomas. To determine the role of Foxm1 in recruitment of tumor-associated macrophages, a mouse line with macrophage-specific Foxm1 deletion was generated (macFoxm1
Introduction
Foxm1 is a member of the Forkhead box (Fox) family of transcription factors, which is expressed in all proliferating cells, including epithelial cells, macrophages and endothelial cells (Korver et al., 1997; Yao et al., 1997; Ye et al., 1997; Zhao et al., 2006) . Consistent with an important role of Foxm1 in cellcycle progression, increased expression of Foxm1 was found in many human tumors (reviewed by Costa et al., 2005; Myatt and Lam, 2007; Kalin et al., 2011, and Kalin et al., 2006) . Increased Foxm1 expression in human lung adenocarcinomas and squamous cell carcinomas was associated with increased proliferation of tumor cells (Kim et al., 2006) . Transgenic overexpression of Foxm1 using Rosa26-Foxm1 mice significantly increased lung tumorigenesis induced by 3-methylcholanthrene (MCA)/butylated hydroxytoluene (BHT; 3,5-di-t-butyl-4-hydroxytoluene) . Ubiquitous deletion of Foxm1 in Mx-Cre/ Foxm1 fl/fl mice significantly reduced the number and size of urethane-induced lung adenomas (Kim et al., 2006) . Although these studies demonstrated a critical role of Foxm1 in lung tumorigenesis, specific requirements for Foxm1 in distinct cell populations within the lung remain unclear. Recently, we demonstrated that conditional deletion of Foxm1 in respiratory epithelial cells, the precursors of tumor cells, caused a striking delay in the initiation and progression of lung tumors in vivo .
Tumor lesions consist of tumor cells as well as stromal and inflammatory cells, which contribute to the tumorpromoting microenvironment (de Visser et al., 2006) . The relationship between inflammation and cancer pathogenesis has been extensively studied (Coussens and Werb, 2002; Porta et al., 2009) . Epithelial neoplasia is initiated by mutations, but cells often remain dormant until promotional events recruit and activate inflammatory cells within the lesion. Activated inflammatory cells stimulate the growth and progression of epitheliumderived tumors (Balkwill and Mantovani, 2001) .
Accumulating evidence has shown a clear correlation between increased numbers of infiltrating macrophages and a poor prognosis in various mouse and human malignancies, including colon, breast, lung and prostate cancers (Baron and Sandler, 2000; Ernst and Gold, 2000; Bingle et al., 2002; Borsig et al., 2002) .
Although recent studies have focused on cytokine/ chemokine-dependent signaling mechanisms critical for macrophage recruitment to tumors, the transcriptional regulation of this process is relatively unknown. The present study was designed to determine the cell-specific role of Foxm1 in macrophages during formation of lung tumors using a transgenic mouse line with macrophagespecific Foxm1 deletion.
Results

Foxm1 deficiency in myeloid cells does not alter the number of macrophages in untreated lungs
To address the macrophages-specific role of Foxm1, we generated conditional knockout mice containing LoxPflanked exons 4-7 of the Foxm1 gene (Foxm1 fl/fl ) and a LysM-Cre transgene (LysM-Cre/Foxm1 fl/fl or mac Foxm1 À/À mice). In LysM-Cre mice, Cre recombinase (Cre) is expressed in myeloid cells owing to targeted insertion of Cre cDNA into the endogenous lysozyme M gene locus. Previous lineage-tracing studies demonstrated that Cre-mediated recombination in LysM-Cre mice occurs in 85-98% of macrophages and 100% of neutrophils (Clausen et al., 1999) . macFoxm1 À/À mice were fertile with no obvious abnormalities. Deletion of Foxm1 from macrophages and granulocytes did not change the morphological structure of the lung, and alveolar macrophages were present both in control Foxm1 fl/fl and macFoxm1 À/À lungs ( Figure 1a ). Immunostaining for the macrophage-specific Mac-3 antigen demonstrated that the total number of alveolar macrophages in control and macFoxm1 À/À mice was similar (Figures 1a and b) . In peripheral blood, no differences were found in either total leukocyte counts or differential cell counts (Figure 1d , left and middle panel). Flow-cytometric analysis of the peripheral blood confirmed that the number of monocytes (CD11b
cells) was similar in the macFoxm1
À/À and control mice (4.0±0.3% versus 3.7 ± 0.6% for monocytes, and 46.4 ± 3.2% versus 49±4.5% for granulocytes). Flow-cytometric analysis of bone marrow (BM) cells showed no significant changes in the numbers of monocytes and granulocytes between macFoxm1 À/À and control mice ( Figure 1d , right panel). Furthermore, similar numbers of monocytes and macrophages (Supplementary Figure 1) were present in the BM, blood and lungs of 7-month-old control and macFoxm1 À/À mice, suggesting that Foxm1 deletion did not influence the total number of these cells in older animals.
Bronchoalveolar lavage (BAL)-derived cells consisted primarily of macrophages (495%). Both the viability and the cell numbers of BAL macrophages were similar in control and macFoxm1 À/À mice (data not shown). To determine the efficiency of Foxm1 deletion, Foxm1 mRNA in BAL-derived macrophages was examined by quantitative real-time RT-PCR (qRT-PCR). Compared with control mice, a 90% decrease in Foxm1 mRNA was found in BAL macrophages from macFoxm1 À/À mice (Figure 1c) , confirming efficient Foxm1 deletion from macrophages.
Foxm1 deletion from macrophages reduced the number and size of lung tumors induced by MCA/BHT To determine the role of Foxm1 in tumor-associated macrophages, experimental macFoxm1 À/À and control male mice were subjected to a MCA/BHT lung tumor induction/promotion protocol. MCA is a mutagen found in tobacco smoke, which serves as a tumor initiator. BHT is a phenolic antioxidant, which promotes lung tumors by inducing pulmonary inflammation with macrophage infiltration (Marino and Mitchell, 1972; Adamson et al., 1977) . Thirty weeks after MCA injection, mouse lungs were harvested and examined for lung tumors. The total number of lung tumors and tumor size were significantly decreased in macFoxm1 À/À mice compared with control Foxm1 fl/fl mice ( Figure 2a ). Thus, Foxm1 deletion from macrophages was sufficient to decrease lung tumor formation after MCA/BHT treatment.
The number of macrophages in macFoxm1
À/À tumors was decreased Histological examination confirmed the reduced size of lung tumors in macFoxm1 À/À mice and showed that these tumors showed morphological characteristics of lung adenomas (Figure 2b ). The number of Ki-67-positive tumor cells was significantly decreased in the macFoxm1 À/À lungs compared with control Foxm1 fl/fl lungs ( Figure 2c ). No differences were found in the number of apoptotic cells in tumors from control and macFoxm1 À/À mice (data not shown). Interestingly, tumors from macFoxm1 À/À mice contained fewer tumor-infiltrating macrophages, as demonstrated by immunostaining for Mac-3 (Figure 2d ). No significant differences in the number of neutrophils were found in the macFoxm1 À/À tumors (data not shown), indicating that Foxm1 deletion did not influence neutrophil recruitment into tumor sites. The percentage of peripheral blood monocytes present in control and macFoxm1 À/À mice after MCA/BHT treatment was also not significantly different (Supplementary Figure 2) . The percentage of monocytes in the BM of macFoxm1 À/À animals was increased, suggesting that the decreased number of macrophages in the macFoxm1 À/À lungs was not the attributed to decreased monocyte generation in the BM. Thus, deletion of Foxm1 from macrophages impaired tumor growth, decreased proliferation of tumor cells and reduced the number of tumor-infiltrating macrophages.
macFoxm1
À/À mice are resistant to BHT-induced lung inflammation Previous studies demonstrated that BHT promotes lung tumorigenesis by inducing pulmonary inflammation and macrophage infiltration into the lung tissue (Malkinson et al., 1997; Blaine et al., 2005) . To assess the effect of Foxm1 deletion on pulmonary inflammation at early stages of tumor promotion, the lungs of macFoxm1 À/À mice and control littermates were collected 2-5 days after the first BHT injection. Lung inflammation was examined by hematoxylin and eosin (H&E) staining. Reduced number of inflammatory cells in the alveolar region, diminished lung congestion and decreased thickening of the alveolar septae were observed in macFoxm1 À/À mice at 2 and 5 days after BHT treatment (Figure 3a) . A decrease in the number of inflammatory cells was also observed in the perivascular and peribronchial areas of macFoxm1 À/À lungs ( Figure 3b ). qRT-PCR analysis of total lung RNA demonstrated decreased mRNA levels of several inflammatory mediators, including cyclooxygenase-2 (Cox2), macrophageinhibitory protein-1a (MIP-1a), iNOS, interleukin-6 (IL-6) and MIP-2, in macFoxm1 À/À lungs ( Figure 3c ). However, systemic inflammation after BHT treatment was similar in control and macFoxm1 À/À mice, as indicated by similar protein levels of Cox-2, IL-6, IL-1b, CCL2 and CCL3 in blood serum from these 
À/À and control mice (right panel). Magnifications: Â 200 (a, upper and middle panels) and Â 400 (a, bottom panel). P-value o0.05 is shown by asterisk (*). (Figure 3d ). These results indicate that macrophage-specific deletion of Foxm1 reduced the severity of pulmonary inflammation at early stages of tumor promotion, without changing the systemic inflammatory response to BHT treatment.
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A decreased number of inflammatory cells was observed in BAL from BHT-treated macFoxm1 À/À lungs ( Figure 4c ). Whereas the number of macrophages was significantly reduced, the number of neutrophils and lymphocytes were not changed ( Figure 4c ). These results are consistent with the diminished lung inflammation in macFoxm1 À/À mice found by histological evaluation (Figures 3a and b) and by gene expression profiling ( Figure 3c ). The number of macrophages in lung tissue was determined by immunohistochemistry using macrophage-specific Mac-3 antibodies. Two and 5 days after BHT injection, the number of Mac-3-positive cells was significantly decreased in macFoxm1 À/À lungs when compared with controls ( Figures 4a and b) . Thus, deletion of Foxm1 from myeloid cells reduced the number of macrophages in BHT-treated lungs, without influencing the number of neutrophils or lymphocytes.
Proliferation of macFoxm1
À/À macrophages is reduced Foxm1 protein was not detected in quiescent lungs by immunohistochemistry, but was dramatically induced These results are consistent with previous studies demonstrating that Foxm1 induces cellular proliferation in various cell types (Balli et al., 2011) . Thus, deletion of Foxm1 decreased the proliferation of macrophages in injured lungs.
Foxm1 deficiency reduced macrophage migration in vitro
The observed decrease in the number of macrophages in the macFoxm1 À/À lung tumors could be the result of impaired macrophage migration. Macrophages were isolated from macFoxm1 À/À or control mice, and in vitro migration was assessed by a Transwell invasion chamber assay. The purity of isolated macrophages was similar (91.4% ± 4.1 for control macrophages and 87.8%±5.7 for macFoxm1 À/À macrophages) as demonstrated by flow cytometry. The viability of isolated macrophages was similar for both groups of mice. Reduced Foxm1 mRNA (Figure 6a ) was associated with a decreased migration of macFoxm1 À/À macrophages through the chamber membrane (Figure 6b ). When RNA was prepared from control and macFoxm1 À/À macrophages that were able to migrate through the membrane, no differences were found in the mRNA levels of Foxm1 or its targets, Cyclin-B1, Cyclin-D1 and Cdc25b (Supplementary Figure  3B) . These results suggest that macFoxm1 À/À macrophages that migrated through the Transwell membrane had incomplete Foxm1 deletion. Thus, Foxm1 is essential for macrophage migration in vitro. À/À mice. ELISAs were used to measure Cox-2 and IL-6 protein levels in mouse serum at day 2 after BHT treatment. IL-1b, CCL2 and CCL3 were measured in mouse serum using Multiplex assay. P-value o0.05 is shown by asterisk (*).
Role of Foxm1 in TAM recruitment D Balli et al
Foxm1 regulates the expression of genes critical for pulmonary inflammation and macrophage migration To identify potential target genes regulated by Foxm1 in macrophages, BAL macrophages from macFoxm1 À/À and control mice were used to prepare total RNA. In control mice, BHT treatment induced Foxm1 expression in BAL macrophages, coinciding with increased expression of pro-inflammatory genes (Figure 6c ). However, in macFoxm1 À/À mice, BHT treatment failed to induce Foxm1 expression in macrophages to the same levels as in control mice, being consistent with efficient Foxm1 deletion (Figure 6c ). Foxm1 deficiency in BHT-treated macFoxm1 À/À BAL macrophages was associated with decreased mRNA levels of Cdc25b phosphatase and Cox-2, both of which are direct Foxm1 target genes (Wang et al., 2005 . Reduced expression of Cdc25b and Cox-2 was also observed in macFoxm1 À/À macrophages isolated from the lung tissues of BHT-treated mice by flow cytometry-based cell sorting (Figure 6d) . mRNAs encoding inflammatory mediators, iNOS and IL-6, were significantly reduced in both the BAL macrophages ( Figure 6c ) and the pulmonary macrophages (Figure 6d ) of BHT-treated macFoxm1 À/À mice (Figures 6c and d) . Generation of reactive oxygen and nitrogen species by macrophages during chronic inflammation is known to cause genomic alterations in epithelial cells promoting tumorigenesis (Kanwar et al., 2009) . Thus, the reduced expression of iNOS and other pro-inflammatory genes may contribute to decreased tumorigenesis observed in macFoxm1 À/À mice. However, no differences were found in the mRNA levels of the pro-inflammatory IL-1a and IL-1b cytokines (Figure 6d ), suggesting that Foxm1 does not regulate the expression of these genes. Arginase1 and IL-12 mRNAs were not changed (Figure 6d ), suggesting that Foxm1 is dispensable for macrophage polarization in this mouse model. Expression of several chemokine genes, CCL3 (MIP-1a), CXCL2 (MIP-2), CX 3 CL1 and matrix metalloproteinase-12 (MMP-12), was decreased in BAL and pulmonary macFoxm1 À/À macrophages (Figures 6c and d ). As these genes are known to regulate the migration of macrophages to the lung (Murdoch et al., 2004; Nenan et al., 2005) , their decreased expression may contribute to the decreased numbers of infiltrating macrophages in BHT-treated macFoxm1 À/À lungs.
Decreased expression of CX 3 CR1 and CXCR4 in macFoxm1 À/À monocytes Expression of chemokine and cytokine receptors critical for macrophage migration was examined in pulmonary macrophages and their monocytic precursors isolated from BHT-treated lungs. Decreased mRNA levels of CSF-R1 and IL-6Rb were found in macFoxm1 À/À macrophages, but expression of these genes was not changed in macFoxm1 À/À monocytes (Figures 7a and b) . By contrast, macFoxm1 À/À monocytes had reduced CX 3 CR1 and CXCR4 mRNA levels (Figure 7b ), both genes being critical for monocyte recruitment into the lungs in response to different stimuli (Srivastava et al., 2005; Zhang and Patel, 2010; Sanchez-Martin et al., 2011) . CCR2 mRNA was not changed (Figure 7b ). 
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promoter is a direct target of the Foxm1 transcription factor As Foxm1-deficient monocytes showed decreased CX 3 CR1 mRNA (Figure 7b ) and the promoter region of the mouse CX 3 CR1 gene contained several potential Foxm1-binding sites, we investigated whether Foxm1 directly bound to and transcriptionally activated the promoter region of the CX 3 CR1 gene. Two potential Foxm1-binding sites were found in the À1.0-kb promoter region of the mouse CX 3 CR1 gene (Figure 7d ). Chromatin immunoprecipitation assays were used to determine whether Foxm1 protein directly binds to the CX 3 CR1 promoter region in mouse Raw264.7 macrophages. The Foxm1 protein specifically bound to the À835/À842-bp binding site (but not to the À337/À343-bp site), as demonstrated by the ability of CMV-Foxm1 to induce the binding of the Foxm1 protein to the CX 3 CR1 promoter DNA (Figure 7c ). To determine whether the binding of Foxm1 results in the transcriptional activation of the CX 3 CR1 promoter, co-transfection experiments were performed using a CMV-Foxm1b expression vector (Kim et al., 2005) and a Luc reporter driven by the À1.0-kb CX 3 CR1 promoter region. Co-transfection of the CMV-Foxm1b expression vector significantly increased Luc activity when compared with a CMV-empty vector (Figure 7d ). Together, these results demonstrate that Foxm1 binds to and transcriptionally activates the À1.0-kb CX 3 CR1 promoter region, suggesting that CX 3 CR1 gene is a direct Foxm1 target. À/À or control mice (n ¼ 3 mice per group) were collected 5 days after BHT injection and were used to prepare total RNA for qRT-PCR. b-Actin mRNA was used for normalization. (d) Decreased expression of pro-inflammatory genes in pulmonary macrophages purified from BHT-treated macFoxm1 À/À lungs. Using flow cytometry-based sorting, pulmonary macrophages were isolated from macFoxm1 À/À or control mice (n ¼ 3 mice per group) 5 days after BHT injection and were used to prepare total RNA for qRT-PCR. b-Actin mRNA was used for normalization. Expression below detection levels are marked as ND. (not detected). P-value o0.05 is shown by asterisk (*).
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Discussion
Using a novel macFoxm1 À/À conditional knockout mouse line in which Foxm1 was selectively deleted from macrophages, we found diminished lung tumorigenesis and a decreased number of tumor-associated macrophages after MCA/BHT treatment. Foxm1-deficient monocytes failed to migrate into the lungs at the early stages of tumor promotion. Our data are consistent with previous studies showing that macrophage infiltration promoted tumor growth Mantovani et al., 2008) . In the present study, we established that Foxm1 is a critical transcriptional regulator of various macrophage functions, such as migration to the lung, secretion of pro-inflammatory cytokines and macrophage proliferation in response to MCA/BHT.
The MCA/BHT tumor induction/promotion protocol closely resembles the initial stages of lung carcinogenesis in human smokers. MCA is a tobacco-derived mutagen and BHT is a tumor-promoting agent. BHT undergoes pulmonary metabolism in mice, causing pulmonary inflammation, macrophage infiltration and necrosis of alveolar type-I epithelial cells, with compensatory hyperplasia of alveolar type-II cells from which lung adenomas originate (Thompson et al., 1987) . Chronic BHT treatment induced persistent chronic pulmonary inflammation with increased numbers of infiltrating macrophages and induced the expression of macrophage-derived cytokines and chemokines (Bauer et al., 2001) . The presence of macrophages was previously found to be critical for pulmonary inflammation and tumorigenesis . In this study, we found that macrophage-specific loss of Foxm1 decreased the number of pulmonary macrophages after BHT treatment. This observation could be the result of decreased migration of monocytes from the circulating blood into lung the tissue and decreased proliferation of resident macrophages. As Foxm1 is a known cell-cycle regulator Myatt and Lam, 2007) , we were not surprised to find that Foxm1 was critical for proliferation of pulmonary macrophages in response to BHT treatment. Interestingly, Foxm1 was dispensable for proliferation of hepatic macrophages in response to carbon tetrachloride treatment (Ren et al., 2010) . Our data suggest that Foxm1 has distinct roles in different macrophage populations and/or different tissue environments . In support of this Role of Foxm1 in TAM recruitment D Balli et al hypothesis, different mechanisms of cell migration were found in hepatic and pulmonary monocytes (Ren et al., 2010 , and this paper). In both injury models, recruitment of monocytes to injured tissues was significantly reduced by Foxm1 deletion. However, during liver injury downregulation of the chemokine receptor CCR2 was responsible for reduced migration of Foxm1-deficient monocytes and CCR2 was shown to be a direct target of Foxm1 (Ren et al., 2010) . Interestingly, CCR2 was not changed in Foxm1-deficient pulmonary monocytes after MCA/BHT treatment, whereas expression of the CX 3 CR1 and CXCR4 chemokine receptors was decreased. Both CX 3 CR1 and CXCR4 pathways are critical for monocyte recruitment during pulmonary inflammation as demonstrated by previous studies (Srivastava et al., 2005; Zhang and Patel, 2010 ; Sanchez-Martin et al., 2011). Moreover, the mouse CX 3 CR1 promoter region has several potential Foxm1-binding sites; Foxm1 directly binds to the CX 3 CR1 promoter DNA; and the transcriptional activity of the CX 3 CR1 promoter was induced by Foxm1 in co-transfection experiments. These results suggest that CX 3 CR1 is a direct target of Foxm1 in pulmonary monocytes. Thus, while Foxm1 is required for recruitment of monocytes into injured liver and lung tissues, different chemokine signaling pathways are regulated by Foxm1 in these organs.
Previous studies demonstrated that MIP-1a and/or MIP-2 mediate BHT-induced monocyte recruitment (Murdoch et al., 2004) . Moreover, MIP-1a levels were elevated in non-small cell lung cancer patients, correlating with increased infiltration of macrophages into tumor regions (Arenberg et al., 2000; Meyer et al., 2006) . In the present study, both MIP-1a and MIP-2 fl/fl monocytes to BHT-treated macFoxm1 À/À mice increased pulmonary inflammation characterized by thickening of alveolar septae (upper panels) and increased perivascular infiltration of inflammatory cells (bottom panels). The numbers of macrophages in macFoxm1 À/À lungs were restored to control levels after adoptive transfer (bar histogram). Statistically significant differences with P-value o0.01 are indicated by ***.
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were decreased in BHT-treated macFoxm1 À/À macrophages, suggesting that decreased expression of these genes may contribute to decreased migration of Foxm1-deficient macrophages (Figure 9 ). Furthermore, MMP-12 mRNA levels were reduced in macFoxm1 À/À macrophages. MMP-12 is upregulated in lung cancer as compared with normal tissues and has been associated with decreased survival (Kleiner and Stetler-Stevenson, 1999; Heist et al., 2006) . Studies using MMP-12 À/À mice demonstrated that macrophage recruitment to the lung was MMP-12-dependent after long-term exposure to cigarette smoke (Hautamaki et al., 1997) . The macrophage recruitment observed in response to cigarette smoke was linked to the elastolytic properties of MMP-12 (Nenan et al., 2005) . Thus, MMP-12 reduction in macFoxm1 À/À macrophages may contribute to decreased recruitment of macrophages into MCA/BHT-treated lungs. As potential Foxm1-binding sites are present within the promoter regions of the MIP-1a, MIP-2 and MMP-12 genes, Foxm1 may have a role in the transcriptional activation of these macrophage genes during pulmonary inflammation and tumorigenesis.
Decreased inflammation in macFoxm1 À/À mice was associated with reduced expression of pro-inflammatory cytokines, including iNOS, Cox-2, IL-1b and IL-6. During chronic inflammation, macrophage-generated reactive oxygen species induce DNA damage in proliferating cells by forming peroxynitrite, a mutagenic agent (Lala and Chakraborty, 2001) . Repeated tissue damage and regeneration of tissue in the presence of reactive oxygen species leads to genomic alterations, including point mutations, deletions or rearrangements (Faux et al., 2009) . Cox-2 and reactive oxygen species stimulate tumor growth and metastasis by promoting migration, invasion and angiogenesis (Lala and Chakraborty, 2001 ). The cytokines IL-1b and IL-6, when persistently produced at chronic inflammatory sites, stimulate the proliferation of DNA-damaged tumor cells and promote tumor formation. In this study, we found that Foxm1-deficient macrophages produced significantly lower levels of IL-1b and IL-6. In addition, the total number of macrophages was decreased in macFoxm1 À/À tumors, likely causing even greater decrease in the secretion of these stimulatory factors. Therefore, reduced production of mitogenic cytokines by tumor-associated macrophages can contribute to decreased proliferation of tumor cells in macFoxm1 À/À mice. Altogether, our results demonstrated that Foxm1 influenced various macrophage functions critical for pulmonary inflammation and tumor promotion (Figure 9 ).
In summary, Foxm1 ablation in macrophages reduced the number and size of lung tumors induced by MCA/ BHT. Decreased tumorigenesis in macFoxm1 À/À mice was associated with a diminished number of proliferating tumor cells, impaired recruitment of tumor-associated macrophages and decreased expression of proinflammatory genes. Macrophage-specific ablation of Foxm1 decreased lung inflammation during the early stages of tumor promotion, leading to decreased lung tumorigenesis ( Figure 9 ). Thus, Foxm1 may represent a promising target for development of new therapeutic approaches to reduce tumor-promoting pulmonary inflammation.
Materials and methods
Further details and additional methods are provided in the Supplementary information. The MCA/BHT lung tumor induction/promotion protocol MCA (Sigma, St Louis, MO, USA) was administered as a single intraperitoneal injection (15 mg/g of body weight) followed by six weekly intraperitoneal injections with BHT (300 mg/g of body weight). BHT (Sigma) was dissolved in corn oil at a concentration 30 mg/ml. Mice were killed 30 weeks after MCA injection and lung tumors were counted with a dissecting microscope . To study the role of Foxm1 during tumor induction, mice were killed 1, 2, 3 and 5 days after the first BHT injection. The lungs were used to prepare total RNA or were fixed and embedded into paraffin blocks . Figure 9 Role of Foxm1 in monocytes and macrophages during lung tumorigenesis. After Foxm1 deletion from monocytes, expression of CX 3 CR1 and CXCR4 is decreased, causing reduced recruitment of monocytes to the lung. Foxm1 deficiency in pulmonary macrophages results in decreased expression of IL-6R, MIP1a, MIP2 and MMP12, inhibiting macrophage migration. Foxm1-deficient macrophages showed diminished the levels of Cox-2, iNOS and IL-6 mRNA, resulting in decreased pulmonary inflammation in macFoxm1 À/À mice. The cell-cycle-regulatory gene Cdc25b, a known Foxm1 target, was decreased in macFoxm1 À/À macrophages, which is consistent with decreased proliferation of these cells. Impaired migration, proliferation and expression of pro-inflammatory cytokines in cells of macrophage lineage inhibited BHT-induced pulmonary inflammation, decreasing lung tumorigenesis in macFoxm1 À/À mice. 
were quantified using different fluorochromes or biotin-conjugated antibodies. All antibodies were purchased from eBiosciences (eBiosciences, San Diego, CA, USA), unless otherwise stated. The following monoclonal antibodies were used: F4/80 (BM8), CD11b (M1/70), Ly-6C(HK1.4), Ly-6G(1A8; Biolegend, San Diego, CA, USA) and M-CSFR(AFS98). Biotinylated antibodies were visualized with streptavidin-PE-Cy7. Dead cells were excluded using 7-aminoactinomycin-D (eBiosciences). Data were acquired with an LSRII flow cytometer (BD Biosciences, San Jose, CA, USA). Spectral overlap was compensated using the FACSDiVa software (BD Biosciences) and analyzed using the FlowJo software (Treestar Inc., Ashland, OR, USA). Cytokines in blood serum were measured using Multiplex kits following the manufacturer's protocol (Millipore, Billerica, MA, USA) and conducted by the Cytokine and Mediator Measurement Core at the Cincinnati Children's Hospital Medical Center. Chromatin immunoprecipitation assay Raw264.7 mouse macrophage cells were transfected by electroporation with either CMV-Foxm1 or CMV-empty using the Neon transfection system following the manufacturer's protocol (Invitrogen, Carlsbad, CA, USA). Twenty-four hours after transfection, cells were cross-linked by addition of formaldehyde, sonicated and used for immunoprecipitation using a Foxm1 rabbit polyclonal antibody (C-20; Santa Cruz Biotechnology, Santa Cruz, CA, USA) as described previously (Balli et al., 2011) . DNA fragments were between 500 and 1000 bp in size. Reversed cross-linked chromatin immunoprecipitation DNA samples were subjected to qRT-PCR using oligonucleotides specific to the promoter regions of mouse CX3CR1: À957/À802 (5 0 -GAAAAGGACACGGAGTCGG TG-3 0 and 5 0 -TGTCCCCACTTCAGCTCTTGTTTT-3 0 ) and À527/À385 (5 0 -TATGGTCAGTGGTCAGCGAACC-3 0 and 5 0 -GCAGCACACAAGTCAGGTCTCAAG-3 0 ). Binding of Foxm1 was normalized to the DNA of the samples immunoprecipitated with isotype control serum.
Cloning of the mouse CX 3 CR1 promoter region and luciferase (LUC) assay We used PCR of mouse genomic DNA to amplify the À970 to þ 87-bp region of mouse CX 3 CR1 promoter (GenBank number NC_000075.5) using the following primers: 5 0 -TCCC CCGGGAGTTTAGCAGAAATGAATAAGGACACGG-3 0 and 5 0 -TCCCCCGGGAGTTTAGCAGAAATGAATAAG GACACGG-3 0 . The PCR product was cloned into a pGL2-Basic firefly LUC reporter plasmid (Promega, Madison, WI, USA) and verified by DNA sequencing. U2OS cells were transfected with CMV-Foxm1b or CMV-empty plasmids, as well as with the LUC reporter driven by the À1-kb CX 3 CR1 promoter region (CX 3 CR1-LUC). CMV-Renilla was used as an internal control to normalize transfection efficiency. A dual LUC assay (Promega) was performed 24 h after transfection as described previously .
Isolation and adoptive transfer of monocytes during BHT lung injury Monocyte-enriched cells were isolated from the BM of Foxm1 fl/fl mice as described (Ren et al., 2010) . Erythrocytes and neutrophils were removed by Ficoll gradient centrifugation. Cells were incubated with a biotin-conjugated anti-CD115 (M-CSF receptor) antibody (eBioscience) followed by anti-biotin MACS beads (Miltenyi Biotech, Auburn, CA, USA). A positive cell fraction was obtained through magnetic separation and labeled with CFSE as described (Westcott et al., 2009 
Statistical analysis
We used Microsoft Excel to calculate s.d. and statistically significant differences between samples using the Student's t-test. P-values o0.05 were considered statistically significant.
